

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT PURSUANT TO RULE 13.09(2)(a) OF THE LISTING RULES

This announcement is made by Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**” and its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

Reference is made to the announcements made by the Company dated 28 December 2012 and 3 January 2013 (the “**Announcements**”). Capitalised terms not otherwise defined in this announcement shall have the same meaning as in the Announcements.

The Company was informed by the Purchaser that on 6 May 2013, the Purchaser, which is a company listed on the Shenzhen Stock Exchange (stock code: 002422), issued an announcement regarding the Agreements, which stated that the Purchaser has recently obtained the approval from the National Development and Reform Commission (“**NDRC**”) of China (發改外資【2013】No.825) that the NDRC has approved the Purchaser to perform the Disposal (the “**Approval**”).

Notwithstanding, the Purchaser has informed the Company that, apart from the Approval, the Disposal is still under the process of approval by other relevant regulatory authorities in or outside of China in accordance with the relevant domestic provisions of China that the conditions precedent to the completion of the Agreements have not been satisfied as at the date of this announcement.

As the conditions precedent may or may not be fulfilled, shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 6 May 2013

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

The directors of the Company jointly and severally accept full responsibility for accuracy of the information contained in this announcement and the Announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement and the Announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement and the Announcement, the omission of which would make any statement in this announcement and the Announcement misleading.